Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia
Introduction: Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT. Methods: Motor performance was measured with the Movement Assessment Battery for Children (movement-ABC). DNA, from mononuclear blood cells was genotyped for CYP3A5, MDR-1 and MAPT polymorphisms. Results: Motor performance was not significantly affected by CYP3A5 *3/*3 and CYP3A5*1*3 genotypes, MDR-1 polymorphisms or MAPT haplotype. Conclusion: Our data did not show that CYP3A5, MDR-1 or MAPT polymorphisms are linked to impaired motor performance in children after treatment for ALL.
|Keywords||Impaired motor performance, Leukemia, Polymorphisms|
|Persistent URL||dx.doi.org/10.1016/j.leukres.2009.04.027, hdl.handle.net/1765/27735|
Hartman, A, van Schaik, R.H.N, van der Heiden, I.P, Broekhuis, M.J.C, Meier, M, den Boer, M.L, & Pieters, R. (2010). Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leukemia Research: clinical and laboratory studies, 34(2), 154–159. doi:10.1016/j.leukres.2009.04.027